摘要:目的：评价普乐可复(FK506)对肾移植患者免疫抑制作用的疗效和安全性。方法：将70例肾移植患者分为两组。普乐可复组(n=35)：主要用药为普乐可复+硫唑嘌呤(Aza)+泼尼松(Pred)；环孢素A(CsA)组(n=35)：主要用药为CsA+Aza+Pred。结果：观察6个月，普乐可复组急性排斥发生率为0，而CsA组有9例(25.7%)发生急性排斥反应(P<0.05)；普乐可复组的肝毒性和神经毒性反应发生率均比CsA组低(P<0.05)；普乐可复组有3例(8.6%)发生高血糖反应(P>0.05)。结论:普乐可复在肾移植中排斥发生率低，毒副作用小，是一种安全高效的新型免疫抑制剂。

    关键词：普乐可复；环孢素A；肾移植

    Clinical Application of FK506 in Renal Transplantation

    CHEN Kai-jie,et al

    (The Affiliated Hospital of Guangdong Medical College, Guangdong Zhanjiang 524001, China)

    Abstract: Objective: To investigate the immunosuppressive efficacy and safety of FK506 on renal transplant recipients. Method: 70 cases of renal transplant recipients were divided into two groups: FK506 group was treated with FK506+Aza+Pred, CsA group was treated with CsA+Aza+Pred. Result: After six months' observation, there is no acute rejection in FK506 group while 9 patients in CsA group(25.7%) presented acute rejection(P<0.05). Incidence of hepatotoxicity and neurotoxicity in FK506 group was lower than that of CsA group(P<0.05). 3 cases in FK506 group presented high blood glucose (8.6%)(P>0.05). Conclusion: FK506 is a new effective and safe immunity inhibitor in kidney transplant. ......